Performance Review Board Members, 69093 [2013-27501]

Download as PDF Federal Register / Vol. 78, No. 222 / Monday, November 18, 2013 / Notices LeRoy A. Richardson, Chief, Information Collection Review Office, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention. DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2013–27447 Filed 11–15–13; 8:45 am] Agency Information Collection Activities; Proposed Collection; Comment Request; Guidance for Industry on Special Protocol Assessment BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES ACTION: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice. AGENCY: The Centers for Disease Control and Prevention (CDC) located within the Department of Health and Human Services (HHS) is publishing the names of the Performance Review Board Members who are reviewing performance for Fiscal Year 2013. FOR FURTHER INFORMATION CONTACT: Sharon O’Brien, Deputy Director, Executive and Scientific Resources Office, Human Capital and Resources Management Office, Centers for Disease Control and Prevention, 4770 Buford Highway NE., Mailstop K–15, Atlanta, Georgia 30341, Telephone (770) 488– 1781. SUPPLEMENTARY INFORMATION: Title 5, U.S.C. 4314(c)(4) of the Civil Service Reform Act of 1978, Public Law 95–454, requires that the appointment of Performance Review Board Members be published in the Federal Register. The following persons will serve on the CDC Performance Review Boards or Panels, which will oversee the evaluation of performance appraisals of Senior Executive Service members for the Fiscal Year 2013 review period: mstockstill on DSK4VPTVN1PROD with NOTICES SUMMARY: Christine Branche, Co-Chair James Seligman, Co-Chair Barbara Bowman Janet Collins Hazel Dean Jane Gentleman Joseph Henderson Jennifer Parker Tanja Popovic Steve Redd Tom Sinks Kevin Smagh Dated: November 8, 2013. Stacey Hoffman, Acting Director, Division of Executive Secretariat, Centers for Disease Control and Prevention. VerDate Mar<15>2010 17:33 Nov 15, 2013 Jkt 232001 Food and Drug Administration, HHS. Performance Review Board Members BILLING CODE 4163–18–P [Docket No. FDA–2013–N–1394] AGENCY: Centers for Disease Control and Prevention [FR Doc. 2013–27501 Filed 11–15–13; 8:45 am] Food and Drug Administration Notice. The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection in the guidance for industry on special protocol assessment. DATES: Submit either electronic or written comments on the collection of information by January 17, 2014. ADDRESSES: Submit electronic comments on the collection of information to http:// www.regulations.gov. Submit written comments on the collection of information to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, Food and Drug Administration, 1350 Piccard Dr., PI50–400B, Rockville, MD 20850, PRAStaff@fda.hhs.gov. SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501–3520), Federal Agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ‘‘Collection of information’’ is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a 60-day notice in SUMMARY: PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 69093 the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document. With respect to the following collection of information, FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA’s functions, including whether the information will have practical utility; (2) the accuracy of FDA’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology. Guidance for Industry on Special Protocol Assessment—(OMB Control Number 0910–0470)—Extension The ‘‘Guidance for Industry on Special Protocol Assessment’’ describes Agency procedures to evaluate issues related to the adequacy (e.g., design, conduct, analysis) of certain proposed studies. The guidance describes procedures for sponsors to request special protocol assessment and for the Agency to act on such requests. The guidance provides information on how the Agency interprets and applies provisions of the Food and Drug Administration Modernization Act of 1997 and the specific Prescription Drug User Fee Act of 1992 (PDUFA) goals for special protocol assessment associated with the development and review of PDUFA products. The guidance describes the following two collections of information: (1) The submission of a notice of intent to request special protocol assessment of a carcinogenicity protocol and (2) the submission of a request for special protocol assessment. Notification for a Carcinogenicity Protocol As described in the guidance, a sponsor interested in Agency assessment of a carcinogenicity protocol should notify the appropriate division in FDA’s Center for Drug Evaluation and Research (CDER) or the Center for Biologics Evaluation and Research (CBER) of an intent to request special protocol assessment at least 30 days E:\FR\FM\18NON1.SGM 18NON1

Agencies

[Federal Register Volume 78, Number 222 (Monday, November 18, 2013)]
[Notices]
[Page 69093]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-27501]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Performance Review Board Members

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Centers for Disease Control and Prevention (CDC) located 
within the Department of Health and Human Services (HHS) is publishing 
the names of the Performance Review Board Members who are reviewing 
performance for Fiscal Year 2013.

FOR FURTHER INFORMATION CONTACT: Sharon O'Brien, Deputy Director, 
Executive and Scientific Resources Office, Human Capital and Resources 
Management Office, Centers for Disease Control and Prevention, 4770 
Buford Highway NE., Mailstop K-15, Atlanta, Georgia 30341, Telephone 
(770) 488-1781.

SUPPLEMENTARY INFORMATION: Title 5, U.S.C. 4314(c)(4) of the Civil 
Service Reform Act of 1978, Public Law 95-454, requires that the 
appointment of Performance Review Board Members be published in the 
Federal Register. The following persons will serve on the CDC 
Performance Review Boards or Panels, which will oversee the evaluation 
of performance appraisals of Senior Executive Service members for the 
Fiscal Year 2013 review period:

Christine Branche, Co-Chair
James Seligman, Co-Chair
Barbara Bowman
Janet Collins
Hazel Dean
Jane Gentleman
Joseph Henderson
Jennifer Parker
Tanja Popovic
Steve Redd
Tom Sinks
Kevin Smagh

    Dated: November 8, 2013.
Stacey Hoffman,
Acting Director, Division of Executive Secretariat, Centers for Disease 
Control and Prevention.
[FR Doc. 2013-27501 Filed 11-15-13; 8:45 am]
BILLING CODE 4163-18-P